Clinical Trial Update: A Study of SHR3680 in Combination With Docetaxel in the Treatment of mCRPC [Phase 2]

View source ↗

Summary

Phase 2 trial update of SHR3680 in combination with docetaxel for metastatic prostate cancer (mCRPC).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• SHR3680

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Prostate Cancer Metastatic | Phase 2 | Status: UNKNOWN